ARD-353 [4-((2R,5S)-4-(R)-(4-diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2,5-dimethylpiperazin-1-ylmethyl)benzoic acid], a novel nonpeptide delta receptor agonist, reduces myocardial infarct size without central effects. | J Pharmacol Exp Ther;316(1): 423-30, 2006 Jan. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

ARD-353 [4-((2R,5S)-4-(R)-(4-diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2,5-dimethylpiperazin-1-ylmethyl)benzoic acid], a novel nonpeptide delta receptor agonist, reduces myocardial infarct size without central effects.

Watson, Michael J; Holt, Jonathon D S; O'Neill, Scott J; Wei, Ke; Pendergast, William; Gross, Garrett J; Gengo, Peter J; Chang, Kwen-Jen.

Affiliation

Watson MJ; Enhance Biotech Inc., 631 United Drive, Suite 200, Durham, NC 27713, USA.

J Pharmacol Exp Ther ; 316(1): 423-30, 2006 Jan.

Article in En | MEDLINE | ID: mdl-16188952

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Cardiotonic Agents / Receptors, Opioid, delta / Myocardial Infarction / Myocardium Limits: Animals Language: En Journal: J Pharmacol Exp Ther Year: 2006 Document type: Article Affiliation country: Country of publication:

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Cardiotonic Agents / Receptors, Opioid, delta / Myocardial Infarction / Myocardium Limits: Animals Language: En Journal: J Pharmacol Exp Ther Year: 2006 Document type: Article Affiliation country: Country of publication: